We prioritized MTA1 for further analysis because: 1) MTA1 has known tumorigenic properties [54], 2) MTA1 mRNA has been shown to be regulated by FTO in an m6A-dependent manner in CRC cells [52], and 3) the MTA1 promoter is not targeted by ZBTB48 in HEK293 cells, thus reducing the possibility of indirect effects related to the function of ZBTB48 as a transcription factor. The gene discussed is MTA1; the disease is colorectal carcinoma.